

Regimen Reference Order – LYMP – zanubrutinib

ARIA: LYMP – [zanubrutinib]

Planned Course: Once daily until disease progression or unacceptable toxicity
(1 cycle = 30 days)

Indication for Use: Waldenström's Macroglobulinemia

Proceed with treatment if:

ANC equal to or greater than $0.75 \times 10^9/L$ AND Platelets equal to or greater than $50 \times 10^9/L$

❖ **Contact Hematologist if parameters not met**

Treatment Regimen – LYMP – zanubrutinib

Drug	Dose	CCMB Administration Guideline
zanubrutinib	320 mg*	Orally once daily with or without food Swallow whole (Self-administered at home)
*Alternate dosing schedule of 160 mg twice daily may be used at the prescriber's discretion		
zanubrutinib (Brukinsa®) available dosage strength: 80 mg capsule Classification: Cytotoxic, Hazardous		

REQUIRED MONITORING

Baseline

- Hepatitis B serology
- EKG

All Cycles

- CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin as per Physician Orders
- Monitor blood pressure and heart rate for tachycardia and irregular rhythm
- At physician's discretion, EKG to assess for atrial fibrillation if tachycardia or irregular rhythm present

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

INSTRUCTIONS FOR PATIENT

- zanubrutinib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Patients should report signs and symptoms of bleeding (i.e. excess bruising), palpitations, syncope and skin changes
- Patients should use necessary sun protection due to a potential increased risk of skin cancer
- When zanubrutinib is prescribed twice daily, doses of zanubrutinib should be separated by approximately 12 hours
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on zanubrutinib

ADDITIONAL INFORMATION

- Hematologist should be consulted regarding dosing of zanubrutinib pre- and post-surgery for patients undergoing a surgical procedure, including dental surgery, due to risk of bleeding regardless of platelet count